Baraclude therapy launched in India for Hepatitis B patients

New Delhi, July 1 (UNI) Coming as a saviour to the rising number of Hepatitis B patients in India, US-based Bristol-Myers Squibb today launched the Baraclude (Entecavir) therapy here, for the treatment of chronic Hepatitis B virus infection.

Baraclude, an oral anti-viral therapy, designed to block the replication of Hepatitis B virus in the liver, has been launched after getting the approval of the Drug Controller General of India.

''With the approval and launch of Baraclude in India, the company will now be able to address another area of significant unmet medical need,'' Bristol-Myers Squibb India Managing Director Eric Breumier said.

The new therapy is an important step forward for patients and our company, as we seek to realise our mission of extending and enhancing human life by focusing on discovering, developing and providing innovative treatments for serious diseases, he added.

Baraclude is used for the treatment of chronic Hepatitis B virus infection in adults with symptoms of active viral replication and either of persistent elevations in serum aminotransferases (ALT or AST) or histologically active diseases.

In addition, Baraclude is a nucleoside analog, approved for marketing in the US by the US Food and Drug Administration (FDA).

UNI DKS RA KP1908